MATERIAL AND METHODS: Within the group of 47 patients treated with peptide receptor radionuclide therapy (PRRT), four patients were chosen: three with inoperable tumors without liver metastases and one with two lesions in the pancreas and metastases. RESULTS: In all patients, after PRRT, the changes in the sum of the longest diameters of tumors were between -1% and -21%, resulting in stable disease reported [strict Response Evaluation Criteria in Solid Tumors (RECIST)]. But the measurements of tumor volume and attenuation in computed tomography and the tumor to nontumor ratio in somatostatin receptor scintigraphy resulted in different response assessments. CONCLUSIONS: The RECIST standard may be not sufficient to properly assess the therapy response in patients with neuroendocrine tumors.
MATERIAL AND METHODS: Within the group of 47 patients treated with peptide receptor radionuclide therapy (PRRT), four patients were chosen: three with inoperable tumors without liver metastases and one with two lesions in the pancreas and metastases. RESULTS: In all patients, after PRRT, the changes in the sum of the longest diameters of tumors were between -1% and -21%, resulting in stable disease reported [strict Response Evaluation Criteria in Solid Tumors (RECIST)]. But the measurements of tumor volume and attenuation in computed tomography and the tumor to nontumor ratio in somatostatin receptor scintigraphy resulted in different response assessments. CONCLUSIONS: The RECIST standard may be not sufficient to properly assess the therapy response in patients with neuroendocrine tumors.
Authors: Marta Opalińska; Anna Sowa-Staszczak; Anna Grochowska; Helena Olearska; Alicja Hubalewska-Dydejczyk Journal: Front Oncol Date: 2021-11-12 Impact factor: 6.244
Authors: C Merkel; C H Whicher; J Bomanji; K Herrmann; J Ćwikła; N Jervis; S Wait; A Chiti Journal: Eur J Nucl Med Mol Imaging Date: 2020-06 Impact factor: 9.236